We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Demand for the corticosteroid dexamethasone has skyrocketed in the days since the University of Oxford published trial results suggesting the drug could be a game-changer for treating severely ill COVID-19 patients, hospital data shows. Read More
Information gathered from testing patients’ antibody neutralizing capacity “could be used in the development of COVID-19 vaccines and the screening of convalescent plasma for prophylactic and therapeutic use,” the company said. Read More
The blood test will detect both immunoglobulin M (IgM) antibodies — the first antibodies the body makes when it fights a new infection — and immunoglobulin G (IgG) antibodies, which show up later. Read More
Fulcrum Therapeutics has begun a phase 3 clinical trial in the U.S. of its investigational anti-inflammatory drug losmapimod for the treatment of hospitalized COVID-19 patients. Read More
Sanofi has progressed faster than anticipated with a COVID-19 vaccine candidate being developed in collaboration with GlaxoSmithKline (GSK), according to the company’s CEO. Read More
FibroGen has initiated a phase 2 trial of its monoclonal antibody pamrevlumab for the treatment of hospitalized patients with acute COVID-19 infections. Read More
Three high-ranking House Democrats have asked FDA Commissioner Stephen Hahn for more details of the agency’s review process for COVID-19 vaccines. Read More
FDA Commissioner Stephen Hahn assured House lawmakers yesterday that the agency will maintain its regulatory independence in reviewing COVID-19 vaccine candidates, staying at arm’s length from the Trump administration’s Operation Warp Speed, which aims to have an effective vaccine by year’s end. Read More